Efficacy and Safety of BG00012 in MS
Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bmo, Czechia, 656 91
- Faculty Hospital St. Anne
-
Hradec Kralove, Czechia, 500 05
- Faculty Hospital
-
Pardupice, Czechia, 532 03
- Hospital of Pardubice
-
Plzen, Czechia, 304 60
- Faculty Hospital of Plzen
-
Prague, Czechia, 128 02
- General Teaching Hospital
-
-
-
-
-
Bochum, Germany, 44791
- Bochum am St. Josef-Hospital
-
Dusseldorf, Germany, 40225
- Heinrich-Heine-Universität
-
Goettigen, Germany, 37073
- George-August-Universitat Goettigen
-
-
-
-
-
Budapest, Hungary, 1145
- Uzsoki Hospital
-
Debrecen, Hungary, 4012
- University of Debrecen
-
Gyor, Hungary, 9024
- Petz Aladar County Hospital
-
-
-
-
-
Amsterdam, Netherlands, 1081 HV
- VUMC
-
Rotterdam, Netherlands, 3015 GD
- Academic Hospital Rotterdam
-
-
-
-
-
Bialystok, Poland, 15-276
- SamodzielnyPubliczny Szpital Kliniczny
-
Bialystok, Poland, 15-420
- Niesalezny Zespol Opieki Zdrowognej
-
Bydgoszcz, Poland, 85-681
- 10 Wojskowy Szpital Kliniczny z Polikliniką
-
Gdansk, Poland, 80-803
- Wojewodzki Szpital Specjalistczny
-
Katowice-Ligota, Poland, 41-741
- Slaskiej Akademii Medycznej
-
Krakow, Poland, 31-503
- Szpital Uniwersytecki w Krakowie
-
Lodz, Poland, 90-153
- Panstwowy Szpital Kliniczny
-
Warszawa, Poland, 01-097
- Samodzielny Publiczny Centralny Szpital
-
-
-
-
-
Moscow, Russian Federation, 123182
-
Moscow, Russian Federation, 123367
-
Moscow, Russian Federation, 1153682
-
Moscow, Russian Federation, 127018
-
Novgorod, Russian Federation, 603076
-
Novosibirsk, Russian Federation, 630075
-
St. Petersburg, Russian Federation, 197022
-
St. Petersburg, Russian Federation, 194044
-
St. Petersburg, Russian Federation, 194291
-
St. Petersburg, Russian Federation, 197376
-
-
-
-
-
Molndal, Sweden, 431 80
- MS Centrum
-
Stockholm, Sweden, 141 86
- Karolinska University Hospital
-
Stockholm, Sweden, 171 76
- Karolinska University Hospital
-
-
-
-
-
Basel, Switzerland, CH 4.31
- Kantonsspital Basel
-
-
-
-
-
Ankara, Turkey, 6100
- Hacettepe Unisersitesi
-
Istanbul, Turkey, 34303
- Istanbul University
-
Istanbul, Turkey, TR-34390
- University of Instanbul
-
-
-
-
-
London, United Kingdom, SE1 9RT
- Multiple Sclerosis Reseach Clinic
-
London, United Kingdom, WC1N 3BG
- Institute of Neurology
-
Sheffield, United Kingdom, S10 2JF
- Royal Hampshire Hospital
-
Stoke-on-Trent, United Kingdom, ST4 7LN
- University Hospital of North Staffordshire
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Must be 18 to 55 years old, inclusive, at the time of informed consent.
- Must have a confirmed diagnosis of relapsing-remitting MS according to McDonald criteria #1-4 (McDonald et al, 2001; Appendix 2).
- Must have a baseline EDSS between 0.0 and 5.0, inclusive.
- Must have experienced at least one relapse within the 12 months prior to randomization, with a prior cranial MRI demonstrating lesion(s) consistent with MS OR show evidence of Gd-enhancing lesions of the brain on an MRI performed within the 6 weeks.
- Male and female subjects must be willing to take appropriate measures to prevent pregnancy.
Exclusion Criteria:
- Primary progressive, secondary progressive, or progressive relapsing MS (as defined by Lublin and Reingold, 1996 [Appendix 3]).
- History of malignancy.
- History of severe allergic or anaphylactic reactions or known drug hypersensitivity.
- History of abnormal laboratory results indicative of any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, neurologic (other than MS), and/or other major disease.
- History of human immunodeficiency virus (HIV).
- History of drug or alcohol abuse (as defined by the Investigator) within the 2 years prior to randomization.
- An MS relapse that has occurred within the 50 days prior to randomization AND/OR the subject has not stabilized from a previous relapse prior to randomization.
- Body weight >100 kg.
- Positive for hepatitis C antibody and/or positive for hepatitis B surface antigen (HBsAg) at screening.
- Any of the following abnormal blood tests at screening.
- Any previous treatment with FUMADERM®, FAG-201, or BG00012.
- A medication history that precludes entry into the study.
- Female subjects who are currently pregnant or breast-feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The primary endpoint for the primary objective is the total number of MRI lesions at Weeks 12, 16, 20, and 24.
Time Frame: Weeks 12, 16, 20, and 24
|
Weeks 12, 16, 20, and 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The secondary endpoints will include measuring the changes in MRIs from baseline until Week 24, changes in other MS measurements q12 weeks, and the annualized relapse rate and proportion of changes at Weeks 24 and 48.
Time Frame: Weeks 24 and 48
|
Weeks 24 and 48
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ludwig Kappos, Prof, Kantonsspital Basel
- Study Director: Gilmore O'Neill, MB,MRCPI,MMedSc, Biogen
Publications and helpful links
General Publications
- Mehta D, Miller C, Arnold DL, Bame E, Bar-Or A, Gold R, Hanna J, Kappos L, Liu S, Matta A, Phillips JT, Robertson D, von Hehn CA, Campbell J, Spach K, Yang L, Fox RJ. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice. Neurology. 2019 Apr 9;92(15):e1724-e1738. doi: 10.1212/WNL.0000000000007262. Epub 2019 Mar 27.
- Fox RJ, Kita M, Cohan SL, Henson LJ, Zambrano J, Scannevin RH, O'Gorman J, Novas M, Dawson KT, Phillips JT. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr Med Res Opin. 2014 Feb;30(2):251-62. doi: 10.1185/03007995.2013.849236. Epub 2013 Oct 22.
- Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN; BG-12 Phase IIb Study Investigators. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008 Oct 25;372(9648):1463-72. doi: 10.1016/S0140-6736(08)61619-0. Erratum In: Lancet. 2009 Apr 18;373(9672):1340.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Sclerosis
- Physiological Effects of Drugs
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Dimethyl Fumarate
Other Study ID Numbers
Other Study ID Numbers
- C-1900
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.